ReP USP - Resultado da busca

Artigo de periodico
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease (2017)
Stewart, Ralph A. H.; Hadziosmanovic, Nermin; Armstrong, Paul W.; Cannon, Christopher P.; Granger, Christopher B.; Hagström, Emi; Hochman, Judith S.; Koenig, Wolfgang; Lonn, Eva; Nicolau, José C.; Steg, Philippe Gabriel; Vedin, Ola; Wallentin, Lars; White, Harvey D.
Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES, MORTALIDADE, ATIVIDADE FÍSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEWART, Ralph A. H. et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology, v. 70, n. 11, p. 1689-1700, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.08.017. Acesso em: 08 ago. 2024.
APA
Stewart, R. A. H., Hadziosmanovic, N., Armstrong, P. W., Cannon, C. P., Granger, C. B., Hagström, E., et al. (2017). Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology, 70( 11), 1689-1700. doi:10.1016/j.jacc.2017.08.017
NLM
Stewart RAH, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease [Internet]. Journal of the American College of Cardiology. 2017 ; 70( 11): 1689-1700.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.jacc.2017.08.017
Vancouver
Stewart RAH, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease [Internet]. Journal of the American College of Cardiology. 2017 ; 70( 11): 1689-1700.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.jacc.2017.08.017
Artigo de periodico
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial (2016)
Vranckx, Pascal; White, Harvey D.; Huang, Zhen; Mahaffey, Kenneth W.; Armstrong, Paul W.; Van de Werf, Frans; Moliterno, David J.; Wallentin, Lars; Held, Claes; Aylward, Philip E.; Cornel, Jan H.; Bode, Christoph; Huber, Kurt; Nicolau, José C.; Ruzyllo, Witold; Harrington, Robert A.; Tricoci, Pierluigi
Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: FATORES DE RISCO, HEMORRAGIA, DOENÇAS CARDIOVASCULARES, MORTALIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VRANCKX, Pascal et al. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. Journal of the American College of Cardiology, v. 67, n. 18, p. 2135-2144, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2016.02.056. Acesso em: 08 ago. 2024.
APA
Vranckx, P., White, H. D., Huang, Z., Mahaffey, K. W., Armstrong, P. W., Van de Werf, F., et al. (2016). Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. Journal of the American College of Cardiology, 67( 18), 2135-2144. doi:10.1016/j.jacc.2016.02.056
NLM
Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, Moliterno DJ, Wallentin L, Held C, Aylward PE, Cornel JH, Bode C, Huber K, Nicolau JC, Ruzyllo W, Harrington RA, Tricoci P. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 18): 2135-2144.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.jacc.2016.02.056
Vancouver
Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, Moliterno DJ, Wallentin L, Held C, Aylward PE, Cornel JH, Bode C, Huber K, Nicolau JC, Ruzyllo W, Harrington RA, Tricoci P. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 18): 2135-2144.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.jacc.2016.02.056
Artigo de periodico
Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial (2016)
Lopes, Renato D.; Leonardi, Sergio; Neely, Benjamin; Neely, Megan L.; Ohman, E. Magnus; Ardissino, Diego; Hamm, Christian W.; Goodman, Shaun G.; Bhatt, Deepak L.; White, Harvey D.; Prabhakaran, Dorairaj; Martinez, Felipe; Nicolau, Jose C.; Winters, Kenneth J.; Fox, Keith A. A.; Armstrong, Paul W.; Roe, Matthew T.
Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, FÁRMACOS (SISTEMA CARDIOVASCULAR), ESTUDOS RANDOMIZADOS, REVASCULARIZAÇÃO MIOCÁRDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Renato D. et al. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, v. 67, n. 11, p. 1289-1297, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2016.01.034. Acesso em: 08 ago. 2024.
APA
Lopes, R. D., Leonardi, S., Neely, B., Neely, M. L., Ohman, E. M., Ardissino, D., et al. (2016). Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, 67( 11), 1289-1297. doi:10.1016/j.jacc.2016.01.034
NLM
Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 11): 1289-1297.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.jacc.2016.01.034
Vancouver
Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 11): 1289-1297.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.jacc.2016.01.034
Artigo de periodico
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial (2015)
Nicolau, Jose Carlos; Bhatt, Deepak L.; Roe, Matthew T.; Lokhnygina, Yuliya; Neely, Benjamin; Corbalán, Ramón; Leiva-Pons, José L.; Martinez, Felipe; Goodman, Shaun G.; Winters, Kenneth J.; Verheugt, Freek W.A.; Armstrong, Paul W.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Ohman, E. Magnus
Source: American Heart Journal. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, MEDICAMENTO (ADMINISTRAÇÃO E DOSAGEM), ADMINISTRAÇÃO DOS CUIDADOS AO PACIENTE, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, v. 170, n. 4, p. 683-694, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2015.05.017. Acesso em: 08 ago. 2024.
APA
Nicolau, J. C., Bhatt, D. L., Roe, M. T., Lokhnygina, Y., Neely, B., Corbalán, R., et al. (2015). Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, 170( 4), 683-694. doi:10.1016/j.ahj.2015.05.017
NLM
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Vancouver
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Artigo de periodico
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease (2014)
White, Harvey D.; Held, Claes; Stewart, Ralph; Tarka, Elizabeth; Brown, Rebekkah; Davies, Richard Y.; Budaj, Andrzej; Harrington, Robert A.; Steg, P. Gabriel; Ardissino, Diego; Armstrong, Paul W.; Avezum, Alvaro; Aylward, Philip E.; Bryce, Alfonso; Chen, Hong; Chen, Ming-Fong; Corbalan, Ramon; Dalby, Anthony J.; Danchin, Nicolas; De Winter, Robbert J.; Denchev, Stefan; Diaz, Rafael; Elisaf, Moses; Flather, Marcus D.; Goudev, Assen R.; Granger, Christopher B.; Grinfeld, Liliana; Hochman, Judith S.; Husted, Steen; Kim, Hyo-Soo; Koenig, Wolfgang; Linhart, Ales; Lonn, Eva; López-Sendón, José; Manolis, Athanasios J.; Mohler III, Emile R.; Nicolau, José C.; Pais, Prem; Parkhomenko, Alexander; Pedersen, Terje R.; Pella, Daniel; Ramos-Corrales, Marco A.; Ruda, Mikhail; Sereg, Mátyás; Siddique, Saulat; Sinnaeve, Peter; Smith, Peter; Sritara, Piyamitr; Swart, Henk P.; Sy, Rody G.; Teramoto, Tamio; Tse, Hung-Fat; Watson, David; Weaver, W. Douglas; Weiss, Robert; Viigimaa, Margus; Vinereanu, Dragos; Zhu, Junren; Cannon, Christopher P.; Wallentin, Lars
Source: The New England Journal of Medicine. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES (PREVENÇÃO E CONTROLE), ARTERIOSCLEROSE CORONÁRIA, FOSFOLIPASES A, REAÇÃO EM CADEIA POR POLIMERASE, BIOLOGIA MOLECULAR, ANÁLISE SEQUENCIAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WHITE, Harvey D. et al. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. The New England Journal of Medicine, v. 370, n. 18, p. 1702-1711, 2014Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1315878. Acesso em: 08 ago. 2024.
APA
White, H. D., Held, C., Stewart, R., Tarka, E., Brown, R., Davies, R. Y., et al. (2014). Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. The New England Journal of Medicine, 370( 18), 1702-1711. doi:10.1056/NEJMoa1315878
NLM
White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen M-F, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim H-S, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler III ER, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse H-F, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease [Internet]. The New England Journal of Medicine. 2014 ; 370( 18): 1702-1711.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1056/NEJMoa1315878
Vancouver
White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen M-F, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim H-S, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler III ER, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse H-F, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease [Internet]. The New England Journal of Medicine. 2014 ; 370( 18): 1702-1711.[citado 2024 ago. 08 ] Available from: https://doi.org/10.1056/NEJMoa1315878
Artigo de periodico
Prognostic Usefulness of White Blood Cell Count and Temperature in Acute Myocardial Infarction (from the CARDINAL Trial) (2005)
Patel, Manesh R.; Mahaffey, Kenneth W.; Armstrong, Paul W.; Weaver, W. Douglas; Tasissa, Gudaye; Hochman, Judith S.; Todaro, Thomas G.; Malloy, Kevin J.; Rolins, Scott; Therou, Pierre; Ruzyllo, Witold; Nicolau, José Carlos; Granger, Christopher B.
Source: American Journal of Cardiology. Unidade: FM
Subjects: PROGNÓSTICO, CONTAGEM DE LEUCÓCITOS, INFARTO DO MIOCÁRDIO (PATOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PATEL, Manesh R. et al. Prognostic Usefulness of White Blood Cell Count and Temperature in Acute Myocardial Infarction (from the CARDINAL Trial). American Journal of Cardiology, v. 95, n. 5, p. 614-618, 2005Tradução . . Acesso em: 08 ago. 2024.
APA
Patel, M. R., Mahaffey, K. W., Armstrong, P. W., Weaver, W. D., Tasissa, G., Hochman, J. S., et al. (2005). Prognostic Usefulness of White Blood Cell Count and Temperature in Acute Myocardial Infarction (from the CARDINAL Trial). American Journal of Cardiology, 95( 5), 614-618.
NLM
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy KJ, Rolins S, Therou P, Ruzyllo W, Nicolau JC, Granger CB. Prognostic Usefulness of White Blood Cell Count and Temperature in Acute Myocardial Infarction (from the CARDINAL Trial). American Journal of Cardiology. 2005 ; 95( 5): 614-618.[citado 2024 ago. 08 ]
Vancouver
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy KJ, Rolins S, Therou P, Ruzyllo W, Nicolau JC, Granger CB. Prognostic Usefulness of White Blood Cell Count and Temperature in Acute Myocardial Infarction (from the CARDINAL Trial). American Journal of Cardiology. 2005 ; 95( 5): 614-618.[citado 2024 ago. 08 ]
Trabalho de evento-resumo periodico
Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial (2004)
Theroux, Pierre; Armstrong, Paul W.; Gonzales, Lina M.; Mahaffey, Kenneth W.; Hochman, Judith S.; Rollins, Scott; Malloy, Kevin J.; Parish, Thomas; Nicolau, José Carlos; Lavoie, Joel; Granger, Christopher B.
Source: Journal American College of Cardiology. Conference titles: Annual Scientific Session American College of Cardiology. Unidade: FM
Subjects: CARDIOPATIAS, ANGIOPLASTIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
THEROUX, Pierre et al. Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 08 ago. 2024. , 2004
APA
Theroux, P., Armstrong, P. W., Gonzales, L. M., Mahaffey, K. W., Hochman, J. S., Rollins, S., et al. (2004). Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. New York: Faculdade de Medicina, Universidade de São Paulo.
NLM
Theroux P, Armstrong PW, Gonzales LM, Mahaffey KW, Hochman JS, Rollins S, Malloy KJ, Parish T, Nicolau JC, Lavoie J, Granger CB. Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. 2004 ;43 287A.[citado 2024 ago. 08 ]
Vancouver
Theroux P, Armstrong PW, Gonzales LM, Mahaffey KW, Hochman JS, Rollins S, Malloy KJ, Parish T, Nicolau JC, Lavoie J, Granger CB. Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. 2004 ;43 287A.[citado 2024 ago. 08 ]
Artigo de periodico
Effect of pexelizumab, an anti-c5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardia infarction: the complement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial (2003)
Mahaffey, Kenneth W.; Granger, Christopher B.; Nicolau, Jose C.; Ruzyllo, Witold; Weaver, Douglas; Theroux, Pierre; Hochman, Judith S.; Filloon, Thomas G.; Mojcik, Christopher F.; Todaro, Thomas G.; Armstrong, Paul W.
Source: Circulation. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, INFLAMAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAHAFFEY, Kenneth W. et al. Effect of pexelizumab, an anti-c5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardia infarction: the complement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial. Circulation, v. 108, n. 10, p. 1176-1183, 2003Tradução . . Acesso em: 08 ago. 2024.
APA
Mahaffey, K. W., Granger, C. B., Nicolau, J. C., Ruzyllo, W., Weaver, D., Theroux, P., et al. (2003). Effect of pexelizumab, an anti-c5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardia infarction: the complement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial. Circulation, 108( 10), 1176-1183.
NLM
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver D, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW. Effect of pexelizumab, an anti-c5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardia infarction: the complement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial. Circulation. 2003 ; 108( 10): 1176-1183.[citado 2024 ago. 08 ]
Vancouver
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver D, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW. Effect of pexelizumab, an anti-c5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardia infarction: the complement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial. Circulation. 2003 ; 108( 10): 1176-1183.[citado 2024 ago. 08 ]
Artigo de periodico
Pexelizumab, an anti-C5 complement antibody, as adjuntive therapy to primary percutaneos coronary intervention in acute myocardial infarction: The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial (2003)
Granger, Christopher B.; Mahaffey, Kenneth W.; Weaver, Douglas; Theroux, Pierre; Hochman, Judith; Filloon, Thomas G.; Rollins, Scott; Todado, Thomas G.; Ruzyllo, Witold; Armstrong, Paul W.; Nicolau, José C.
Source: Circulation,. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, INFLAMAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GRANGER, Christopher B. et al. Pexelizumab, an anti-C5 complement antibody, as adjuntive therapy to primary percutaneos coronary intervention in acute myocardial infarction: The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation, v. 18, p. 1184-1190, 2003Tradução . . Acesso em: 08 ago. 2024.
APA
Granger, C. B., Mahaffey, K. W., Weaver, D., Theroux, P., Hochman, J., Filloon, T. G., et al. (2003). Pexelizumab, an anti-C5 complement antibody, as adjuntive therapy to primary percutaneos coronary intervention in acute myocardial infarction: The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation,, 18, 1184-1190.
NLM
Granger CB, Mahaffey KW, Weaver D, Theroux P, Hochman J, Filloon TG, Rollins S, Todado TG, Ruzyllo W, Armstrong PW, Nicolau JC. Pexelizumab, an anti-C5 complement antibody, as adjuntive therapy to primary percutaneos coronary intervention in acute myocardial infarction: The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation,. 2003 ; 18 1184-1190.[citado 2024 ago. 08 ]
Vancouver
Granger CB, Mahaffey KW, Weaver D, Theroux P, Hochman J, Filloon TG, Rollins S, Todado TG, Ruzyllo W, Armstrong PW, Nicolau JC. Pexelizumab, an anti-C5 complement antibody, as adjuntive therapy to primary percutaneos coronary intervention in acute myocardial infarction: The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation,. 2003 ; 18 1184-1190.[citado 2024 ago. 08 ]

USP Schools

ReP

Filtros

Authors

Date published

Subjects

Source title

Indexado em